Home/Pipeline/Meridigen‑Stroke

Meridigen‑Stroke

Ischemic Stroke

PreclinicalActive

Key Facts

Indication

Ischemic Stroke

Phase

Preclinical

Status

Active

Company

Meridigen Biotech

About Meridigen Biotech

Taiwanese MSC‑focused biotech developing neuro‑vascular and pulmonary cell therapies.

View full company profile

Therapeutic Areas

Neurology Pulmonology Regenerative Medicine

Other Ischemic Stroke Drugs

Drug	Company	Phase	Status
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Phase 3	Active (US trials with FDA orphan drug designation)
MultiStem	Athersys	Phase 3	Active (subject to funding)
IQool™ System	BrainCool	Clinical Evaluation	Evidence Generation
itMSCs + itNSCs	Stemedica Cell Technologies	Research	Active
BXT-25	BioXyTran	Preclinical	Active
Ischemic Stroke Program	CHS Pharma	Pre-clinical	Active
3K3A-APC	ZZ Biotech	Phase 2/3	Active
Ischemic Stroke Device(s)	Infinity Neuro	Pre-clinical	Active
THDG3	DeckTherapeutics	Pre-clinical	Active
Prometheus-based Gene Therapy	Remedium Bio	Pre-clinical	Active
iNstroke Catheters	iVascularU	Commercial	Active
Dual Thrombolytic Regimen (tPA + HisproUK)	Thrombolytic Science International	Phase 2	Active